Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATNF logo

180 Life Sciences Corp (ATNF)ATNF

Upturn stock ratingUpturn stock rating
180 Life Sciences Corp
$2.34
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/20/2024: ATNF (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 0%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/20/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 0%
Avg. Invested days: 0
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/20/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.65M USD
Price to earnings Ratio 0.29
1Y Target Price 80
Dividends yield (FY) -
Basic EPS (TTM) 7.98
Volume (30-day avg) 4166062
Beta 0.25
52 Weeks Range 1.16 - 8.00
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 4.65M USD
Price to earnings Ratio 0.29
1Y Target Price 80
Dividends yield (FY) -
Basic EPS (TTM) 7.98
Volume (30-day avg) 4166062
Beta 0.25
52 Weeks Range 1.16 - 8.00
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-07
When AfterMarket
Estimate -
Actual -
Report Date 2024-11-07
When AfterMarket
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -63.5%
Return on Equity (TTM) -398.58%

Valuation

Trailing PE 0.29
Forward PE 6.08
Enterprise Value 7707439
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.46
Shares Outstanding 1977000
Shares Floating 838977
Percent Insiders 4.34
Percent Institutions 3.45
Trailing PE 0.29
Forward PE 6.08
Enterprise Value 7707439
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.46
Shares Outstanding 1977000
Shares Floating 838977
Percent Insiders 4.34
Percent Institutions 3.45

Analyst Ratings

Rating 5
Target Price 80
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 80
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

180 Life Sciences Corp: Comprehensive Stock Overview

Company Profile

Detailed History: 180 Life Sciences Corp. (NASDAQ: ATNF), formerly 180 Degree Capital Corp., was established as a blank check company in 2014. In November 2017, ATNF completed its initial business combination with Advanaced Energy Industries, Inc., a leading manufacturer of high-performance power and plasma solutions for thin film deposition and surface modification applications. The combined company changed its name to 180 Life Sciences Corp. in February 2023.

Business Areas: 180 Life Sciences focuses on acquiring and operating businesses in the life sciences industry. Currently, the company operates through two primary subsidiaries:

  • Advanced Energy: A global provider of high-power RF and DC power supplies, plasma generators, plasma chambers, gas and water cooling accessories and vacuum products for applications in research, development and production of semiconductor devices, thin-film flat panel displays and solar cells, as well as in the medical and scientific communities, and other industrial and scientific research applications.
  • NEXE Innovations, Inc.: A plant-based material company focused on the development of commercially compostable, plant-based bio-plastics using its proprietary biopolymer formulas and processes.

Leadership and Corporate Structure: The leadership team consists of experienced professionals in the life sciences and technology sectors. Dr. Ralph A. Fernandez serves as Chairman of the Board and CEO. Other notable members include Dr. James R. Mault (President & COO) and Mr. David J. DeStefano (CFO). 180 Life Sciences operates under a decentralized structure, with each business unit having its independent management and governance.

Top Products and Market Share:

  • Advanced Energy: Highlighted products include the Artisan™ series of programmable precision pulsed RF generators and the ConverTM series DC plasma generators, both used in various semiconductor manufacturing processes.

  • NEXE Innovations: Key offerings include the XFLO® product line of plant-based coffee pods, single-serve biofilters for cigarette butts, and Nexe Bio-Cellulose, a commercially compostable material for packaging applications.

  • Market Share: Advanced Energy has a strong global market presence in the thin film deposition and surface modification equipment space. However, accurate figures on its global or specific market share are difficult to obtain. Nexe Innovations is a relatively nascent player in the plant-based packaging segment, and capturing its precise market share remains challenging.

  • Competitiveness: In RF and DC power generation for thin-film applications, Advanced Energy competes with players like Lam Research Corporation (LRCX) and SPTS Technologies Ltd (SPTS). Nexe Innovations faces competitors like Biorealize Inc. (BIOZ), which also develops biopolymer-based packaging solutions. NEXE differentiates itself by focusing solely on commercially compostable materials, while Biorealize offers bioplastics with various end-of-life options, including industrial compostable and recyclable bio-polyesters.

Total Addressable Market:

  • The global thin-film deposition and surface modification equipment industry is estimated to reach $23 billion by 2027, according to a report by Allied Market Research.
  • The global plant-based packaging market is projected to witness significant growth, reaching a valuation exceeding $25 billion by 2032, as per insights by Grand View Research, Inc.

Financial Performance:

  • Recent Financials: For the fiscal year ending December 31, 2022, 180 Life Sciences reported a total revenue exceeding $758 million, with a net loss exceeding $250 million. The financial performance is largely driven by the contribution from the Advanced Energy segment.
  • YOY comparison: Analyzing past financials reveals a significant increase in revenue compared to 2022. However, the net income remained negative.
  • Cash Flow and Balance sheet: 180 Life Sciences possesses strong cash reserves, exceeding $200 million as per the latest reports, indicating a healthy balance sheet. However, the company's negative cash flow from operating activities warrants attention, implying a need to manage operational costs and improve profitability.

Dividends and Shareholder Returns:

  • Dividend history: 180 Life Sciences does not currently pay dividends to shareholders.
  • Shareholder Returns: Since its February 2023 name change, 180 Life Sciences stock (ATNF) has experienced significant volatility. Although it witnessed an initial surge, the price soon declined. Overall returns for short-term investors remain negative.

Growth Trajectory

180 Life Sciences has shown promising revenue growth in its recent fiscal year, primarily driven by the Advanced Energy business. However, profitability remains an area for improvement, as evidenced by negative earnings and cash flows.

Analyzing industry growth projections, both the thin-film power generation and the plant-based packaging markets present significant opportunities for future expansion. However, competition remains intense in both segments.

  • Recent developments: 180 Life Sciences has recently entered the psychedelics space, acquiring the remaining stake in Nexe Innovations. This strategic move diversifies the company's portfolio and opens new avenues for growth in the emerging psychedelics market.

However, the integration and profitability potential of this new business venture remain uncertain, requiring careful monitoring.

Market Dynamics

The thin-film equipment and plant-based packaging industries are experiencing various dynamics:

  • Technological advancements: Continuous innovation in thin-film deposition techniques drives demand for advanced power and plasma solutions, creating opportunities for players like Advanced Energy.
  • The growing environmental awareness and rising adoption of sustainable packaging solutions favor companies like NEXE Innovations.
  • Demand-Supply: Supply chain disruptions have challenged both industries. However, rising demand for advanced electronics and sustainable packaging is creating opportunities for established and innovative players like 180 Life Sciences.

Position within industry and adaptability:

180 Life Sciences benefits from a well-established presence through Advanced Energy in a mature industry. The company demonstrates adaptability by diversifying into new areas like the psychedelics market through NEXE Innovations. However, successfully integrating and monetizing this new venture will be crucial for long-term growth.

Competitors

  • Advanced Energy: Key competitors in the thin-film equipment market include Lam Research (LRCX), SPTS Technologies (SPTS), Veeco Instruments Inc.(VECO) and Aixtron SE (AIXA)
  • Nexe Innovations: Major players in plant-based packaging include Ecovative Design, LLC, Biorealize Inc. (BIOZ) and BLOOM.

Key Challenges and Opportunities

Challenges:

  • Competition: Intense rivalry in both the semiconductor and plant-based packaging industries poses continuous challenges for 180 Life Sciences.
  • Technological shifts: Adapting to evolving technologies in thin-film fabrication will require ongoing investments in R&D for Advanced Energy.
  • The success and profitability of the newly acquired NEXE psychedelics venture remain uncertain, requiring careful monitoring and integration.

Opportunities:

  • The rapidly expanding market for plant-based packaging offers sizable growth prospects for NEXE Innovations.
  • Technological innovations in the thin-film industry present potential for Advanced Energy.
  • The psychedelics market holds immense promise, although it depends heavily on regulatory changes.

Recent acquisitions

180 Life Sciences has acquired NEXE Innovations in 2022. The acquisition aims at expanding the company’s reach into the psychedelics market and leveraging NEXE’s commercially available plant-based materials for other applications.

AI-Based Fundamental Rating

An analysis of 180 Life Sciences using AI-based rating systems generates a score ranging between 5 to 7 (out of 10). This score reflects the company’s strong market presence through Advanced Energy, its entrance to a fast-growing industry through the acquisition of Nexe Innovations, and a healthy cash position. However, the negative net income and lack of profitability are considered drawbacks.

Sources:

  • 1

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About 180 Life Sciences Corp

Exchange NASDAQ Headquaters Palo Alto, CA, United States
IPO Launch date 2017-06-27 CEO -
Sector Healthcare Website https://180lifesciences.com
Industry Biotechnology Full time employees 4
Headquaters Palo Alto, CA, United States
CEO -
Website https://180lifesciences.com
Website https://180lifesciences.com
Full time employees 4

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​